Get started
Penumbra, Inc.Penumbra, Inc.Penumbra, Inc.

Penumbra, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

PEN trade ideas

Momentum Stock: Penumbra IncPenumbra, Inc. is a global healthcare company focused on innovative therapies. The company designs, develops, manufactures, and markets innovative devices and has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs across two major markets, neuro and vascular. Pricing and Performance Currently priced at $315.10, Penumbra has experienced steady growth with its stock value rising over 687.75% since inception. In the past year alone, the company saw a rise of 113.02%, with an impressive 61.18% in the last 6 months and 38.74% year to date. Even with short-term volatility, as indicated by a decrease of 1.74% over the past week, the longer-term trend has been positive. Financial Highlights Penumbra has a market capitalization of approximately $12 billion. It reported an EBITDA of $41.6 million, highlighting its ability to generate operational profits. However, a price-to-earnings (P/E) ratio of 1964.25 suggests the stock is highly overvalued relative to its earnings. The company does not pay a dividend, indicating that it may be reinvesting its earnings to fuel its high growth. The estimated earnings per share for the current year is $1.53, expected to increase to $2.55 next year, suggesting analysts expect continued growth. Valuation The company's trailing price to earnings ratio, at 1964.25, and forward price to earnings ratio, at 277.77, suggest a high valuation. Moreover, the company's price to sales ratio of over 10 further signals potential overvaluation. However, these high ratios might be justified by the company's strong growth and potential in the market. Share Statistics Penumbra has approximately 38.18 million shares outstanding, with a majority of these (91.3%) held by institutional investors. The relatively low percentage of insider ownership (3.91%) might indicate a lack of confidence from the management, or simply a high level of institutional interest. Technical Analysis The company has a relatively low beta value of 0.54, indicating that the stock is less volatile than the market. Despite the high short ratio of 12.13, the short percent is relatively low at 0.1448, suggesting that the majority of investors are bullish on the stock. Analyst Ratings Out of 12 analysts covering the stock, 8 rate it as a strong buy and 3 as a buy, while only one suggests a hold. No analysts recommend selling. The average target price is $314.22, just below the current stock price, indicating that analysts believe the stock is fairly valued at current levels. Institutional Holdings The stock is highly held by institutions, with FMR Inc, BlackRock Inc, and Vanguard Group Inc being among the largest shareholders. This high level of institutional ownership often signals confidence in the company's outlook. Insider Transactions Recent insider trading activity shows both sales and acquisitions of the company’s shares. The transactions have generally been sales, which might be a cause for concern, as it could indicate that insiders are cashing in on the recent price increase, but this is only one of many factors to consider. Outlook While Penumbra's high P/E ratio might suggest overvaluation, the company's consistent growth, positive earnings forecasts, and high institutional ownership indicate that it may have strong future potential. As always, individual investors should consider their risk tolerance and investment goals before investing. In terms of any kind of short term entry, the stock "reads" as potentially expensive so I would want to wait for a pullback to below and then crossing back up through the low 50's area for the RSI . For risk management, a trailing stop loss of around 12% would have kept you in most of this trade. If it broke below that it could have been a good sign to exit and look for a new entry when the trend resumed. As always how you interpret and decide to act on any results is up to you. This is just data not financial or trading advice and past performance is in no way any guarantee of future performance. Think of it as a way to spot stocks you might be interested in and can add to your watch list and perform further research on and or discuss with your broker. Again. Not trading advice . Industries and companies change. Trends can end. Do your own research / discuss it with your advisor, but might be one to watch.
NYSE:PEN
by zAngus
BUY to PENUMBRAHey my friends, PENUMBRA is in a very important moment in its history we can witness a new historical high. It's in a fake bearish move with a long-legged doji and a weak explosion in traded sell volume. In the TIMEFRAME M1 we see a hammer candle with a high volume of sales emitted she wanted to test the base of the bollinger.But it was also a failure at the bottom of the consolidation zone so she will try to get to the last previous low point. This is found on the basis of making his reversal of trend check of the different bollinger levels to achieve. On the VWAP which will give way and go to the top of the consolidation zone to test it. Great possibility of breaking the price with the return of momentum of the operators in purchase, at the same time the zone for arrival in another and to make a new high. To then go and test the top of the loudspeaker with the symbolic figure of 320.00. Please LIKE & FOLLOW, thank you!
NYSE:PENShort
by stephanelibatd
PEN $297 Target (30%+ Gain Opportunity)PEN is on an upward trend as seen with the three sets of Higher Highs and Higher Lows. We are in the midst of the 3rd "Higher Low" right now. It will likely fall somewhere around here, so right now is the perfect entry point. I set a Stop Loss around $183.55 because this is the low point of the previous "Higher Low." If the price falls below this point, the upward trend will end and the pattern invalidated. When we begin progressing towards the target, I will move my Stop Loss to be breakeven. I've used the previous bull runs as a measure for predicting this next one. They estimate the target to be around $310-$320 before there is a new "Higher Low." To be safe, I've placed my target at $297 (before the psychological resistance of $300). I am unsure whether I will take some profits at $297 (and leave most of it in) or if I will take it all out. Theoretically, a surge past $300 could create an opportunity for an even bigger bull run, but if it rejects off of $300, it could potentially end the upward trend.
NYSE:PENLong
by trufeats
2
Penumbra: Richly-valued but trades well after earningsNov 5th, 3:12 pm $PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M Nov 6th, 9:15 am $PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for $JNJ $MDT or even $EW Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT. PEN
NYSE:PENLong
by KevinBCookca